[12:26 PM] Sean Hart Skip to main content

Monitoring the Oncolytic Effect of Talimogene Iaherparepvec (T-VEC) in Combination with the MEK Inhibitor Trametinib Using Laser Force Cytology™

The ability to rapidly and accurately determine the viral infectivity and oncolytic effects of drug candidates could help improve the speed of oncolytic vaccine R&D, product development, manufacturing, and efficacy monitoring. Here we present the results from monitoring T-VEC infection in melanoma cancer cells using Laser Force Cytology™. LumaCyte’s Radiance® instrument develops an infection metric that correlates well with the initial virus concentration, demonstrating the potential for rapid infectivity and oncolytic measurements using LFC ™.  In addition, through the use of multivariate analysis using LFC ™ data, cells infected with T-VEC and treated with a MEK inhibitor can be differentiated from cells treated with only T-VEC, demonstrating the ability of LFC ™ to capture subtle cellular changes.

View Poster

How will you Harness the Power of Laser Force Cytology™ to Accelerate the Development and Production of Life Saving Therapies Faster than Ever Before?

Speak To An Expert
Close Menu